The unique growth mechanism of ER- tumors makes it difficult to treat ER- breast cancer that has a worse prognosis than ER+ (Tsutsui et al., 2002) with a more aggressive phenotype (Sheikh et al., 1994; Perou et al., 2002). Here, ESR1 is linked to breast carcinoma.